Showing 1 to 7 of 7 results
Liquid Biopsy Shows Promise for Early Detection and Prevention of Breast Cancer Relapse
A new blood test, "liquid biopsy," detects breast cancer relapse earlier than traditional methods, allowing for preventive treatment with camizestrant, showing a 56% reduction in disease progression risk in a clinical trial involving 3000 patients.
Liquid Biopsy Shows Promise for Early Detection and Prevention of Breast Cancer Relapse
A new blood test, "liquid biopsy," detects breast cancer relapse earlier than traditional methods, allowing for preventive treatment with camizestrant, showing a 56% reduction in disease progression risk in a clinical trial involving 3000 patients.
Progress
48% Bias Score
Olaparib Improves Survival Rates for Inherited Breast Cancer
A UK trial found that giving olaparib before surgery to women with early-stage BRCA1 or BRCA2 mutated breast cancer led to 100% survival at 36 months in the treatment group, compared to a 89% survival rate in the control group, potentially benefiting over 1,200 UK women annually.
Olaparib Improves Survival Rates for Inherited Breast Cancer
A UK trial found that giving olaparib before surgery to women with early-stage BRCA1 or BRCA2 mutated breast cancer led to 100% survival at 36 months in the treatment group, compared to a 89% survival rate in the control group, potentially benefiting over 1,200 UK women annually.
Progress
48% Bias Score
Stage Four Lung Cancer Diagnosis in a Never-Smoker Highlights Systemic Issues
A Stanford professor and primary care doctor, age 49, was diagnosed with stage four lung cancer, despite never smoking, highlighting the need for increased research funding and improved patient care for this deadly disease.
Stage Four Lung Cancer Diagnosis in a Never-Smoker Highlights Systemic Issues
A Stanford professor and primary care doctor, age 49, was diagnosed with stage four lung cancer, despite never smoking, highlighting the need for increased research funding and improved patient care for this deadly disease.
Progress
32% Bias Score
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Progress
40% Bias Score
New Drug Shows Promise in Treating Lung Cancer in Non-Smokers
A clinical trial of the drug zongertinib shows promise in treating HER2-mutated lung cancer in non-smokers, with 70% of participants experiencing tumor shrinkage; this offers hope for a previously difficult-to-treat cancer subtype that affects approximately 6,000 non-smokers annually in Spain.
New Drug Shows Promise in Treating Lung Cancer in Non-Smokers
A clinical trial of the drug zongertinib shows promise in treating HER2-mutated lung cancer in non-smokers, with 70% of participants experiencing tumor shrinkage; this offers hope for a previously difficult-to-treat cancer subtype that affects approximately 6,000 non-smokers annually in Spain.
Progress
44% Bias Score
NHS England Approves New Drug for Advanced Breast Cancer
A new drug, capivasertib, is now available on the NHS in England to treat advanced breast cancer, offering a potential benefit to 3,000 women yearly by slowing disease progression and shrinking tumors; it targets the AKT protein and was approved after successful clinical trials showing it doubled th...
NHS England Approves New Drug for Advanced Breast Cancer
A new drug, capivasertib, is now available on the NHS in England to treat advanced breast cancer, offering a potential benefit to 3,000 women yearly by slowing disease progression and shrinking tumors; it targets the AKT protein and was approved after successful clinical trials showing it doubled th...
Progress
40% Bias Score
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Progress
40% Bias Score
Showing 1 to 7 of 7 results